




Ifn

Packet No.: 066872-0038

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant	:	Gil and Donello	Customer No.: 41552
Appl. No.	:	10/735,506	Confirmation No.: 5723
Filed	:	December 11, 2003	CERTIFICATE OF MAILING (37 CFR. § 1.8(a))
Title	:	NOVEL METHODS AND COMPOSITIONS FOR ALLEVIATING PAIN	I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail under 37 CFR 1.8(a) in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on <u>Aug 5, 2004</u> .
Grp./A.U.	:	1614	
Examiner:	:	Unassigned	Marion Wilkes

**INFORMATION DISCLOSURE STATEMENT**

Mail Stop  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.


This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.

SERIAL NO.  
10/735,506

Please charge any shortage in fees due in connection with the filing of this paper, including extension of time fees, to Deposit Account 502624 and please credit any excess fees to such deposit account.

Respectfully submitted,

MCDERMOTT WILL & EMERY LLP



Andrea L. Gashler  
Registration No. 41,029

4370 La Jolla Village Drive, Suite 700  
San Diego, CA 92122  
Telephone: 858.535.9001  
Facsimile: 858.597.1585  
**Date: August 5, 2004**

AUG 09 2004

APPLICANTS:  
Gil and Donello

INFORMATION DISCLOSURE STATEMENT BY

FILING DATE:  
December 11, 2003GROUP: 1614  
CONFIRMATION NO.: 5723

## U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	1.	5,021,410	06/04/91	Burke	514	213	05/22/89
	2.	6,313,172	11/06/01	Chow et al.	514	587	04/13/00
	3.	6,329,369	12/11/01	Chow et al.	514	230.5	12/11/01

## FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATIO N (YES/NO)
	4.	WO 99/28300	06/10/99	PCT			
	5.	WO 01/00586	01/04/01	PCT			
	6.	WO 01/78702	10/25/01	PCT			
	7.	WO 01/78703	10/25/01	PCT			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

	8.	Al-Chaer et al., "A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development," <u>Gastroenterology</u> 119:1276-1285 (2000)
	9.	Altman et al., "Abnormal regulation of the sympathetic nervous system in $\alpha_2$ -adrenergic receptor knockout mice," <u>Mol. Pharm.</u> 56:154-161 (1999)
	10.	Beeley et al., "Synthesis of a selective alpha-2A adrenoceptor antagonist, BRL 48962, and its characterization at cloned human alpha-adrenoceptors," <u>Bioorganic &amp; Med. Chem.</u> 3:1693-1698 (1995)
	11.	Bennett and Xie, "A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man," <u>Pain</u> 33:87-107 (1988)
	12.	Boucher et al., "Potent analgesic effects of GDNF in neuropathic pain states," <u>Science</u> 290:124-127 (2000)
	13.	Bylund et al., "International Union of Pharmacology nomenclature of adrenoceptors," <u>Pharmacol. Rev.</u> 46:121-136 (1994)
	14.	Calzada and Artiñano, "Alpha-adrenoceptor subtypes," <u>Pharm. Res.</u> 44:195-208 (2001)
	15.	Conklin et al., "Substitution of three amino acids switches receptor specificity of Gq alpha to that of Gi alpha," <u>Nature</u> 363:274-276 (1993)
	16.	Dixon et al., "Efficient analysis of experimental observations," <u>Ann. Rev. Pharmacol. Toxicol.</u> 20:441-462 (1980)

Examiner:

Date Considered:

Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY CLIENT-MATTER NO: 66872-038	SERIAL NO. 10/735,506
	APPLICANTS: Gil and Donello	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: December 11, 2003	GROUP: 1614 CONFIRMATION NO.: 5723

17.	Dray, "Neurogenic mechanisms and neuropeptides in chronic pain," <u>Progress in Brain Res.</u> 110:85-94 (1996)
18.	Hein and Kobilka, "Adrenergic receptor signal transduction and regulation," <u>Neuropharmacol.</u> 34:357-366 (1995)
19.	Hein et al., "Gene substitution/knockout to delineate the role of $\alpha_2$ -adrenoceptor subtypes in mediating central effects of catecholamines and imidazolines," <u>Ann. NY Acad. Science</u> 881:265-271 (1999)
20.	Hieble et al., "Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification," <u>J. Med. Chem.</u> 38:3415-3444 (1995)
21.	Kable et al., "In vivo gene modification elucidates subtype-specific functions of $\alpha_2$ -adrenergic receptors," <u>J. Pharm. Exper. Ther.</u> 293:1-7 (2000)
22.	Kamibayashi and Maze, "Clinical uses of $\alpha_2$ -adrenergic agonists," <u>Anesthesiology</u> 93:1345-1349 (2000)
23.	Kim and Chung, "An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat," <u>Pain</u> 50:355-363 (1992)
24.	Maze and Fujinaga, " $\alpha_2$ adrenoceptors in pain modulation," <u>Anesthesiology</u> 92:934-936 (2000)
25.	Messier et al., "High throughput assays of cloned adrenergic, muscarinic, neurokinin, and neurotrophin receptors in living mammalian cells," <u>Pharmacol. Toxicol.</u> 76:308-311 (1995)
26.	Minami et al., "Allodynia evoked by intrathecal administration of prostaglandin E2 to conscious mice," <u>Pain</u> 57:217-223 (1994)
27.	Myers, "The pathogenesis of neuropathic pain," <u>Regional Anesthesia</u> 20:173-184 (1995) 1994 ASRA Lecture.
28.	Roberts et al., "SK&F 104078, a post-junctionally selective $\alpha_2$ -adrenoceptor antagonist in the human saphenous vein in vitro," <u>Arch. Pharmacol.</u> 345:327-332 (1992)
29.	Wang et al., "Antisense RNA/DNA-based techniques to probe adrenergic receptor function," <u>Meth. Mol. Biol.</u> 126:241-258 (2000)
30.	Woolf and Mannion, "Neuropathic pain: Aetiology, symptoms, mechanisms, and management," <u>The Lancet</u> 353:1959-1964 (1999)
31.	Woolf and Salter, "Neuronal plasticity: Increasing the gain in pain," <u>Science</u> 288:1765-1768 (2000)
32.	Yaksh, "Spinal systems and pain processing: Development of novel analgesic drugs with mechanistically defined models," <u>Trends Pharmacol. Science</u> 8:329-337 (1999)
33.	Yaksh and Harty, "Pharmacology of the allodynia in rats evoked by high dose intrathecal morphine," <u>J. Pharmacology Exp. Ther.</u> 244:501-507 (1988)
34.	Young et al., "Novel $\alpha_2$ -adrenoceptor antagonists show selectivity for $\alpha_{2A}$ - and $\alpha_{2B}$ -adrenoceptor subtypes," <u>Eur. J. of Pharmacol.</u> 168:381-386 (1989)